Atossa Therapeutics (NASDAQ:ATOS) Shares Cross Above 200-Day Moving Average of $1.41

Atossa Therapeutics, Inc. (NASDAQ:ATOS) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.41 and traded as high as $1.47. Atossa Therapeutics shares last traded at $1.42, with a volume of 502,328 shares traded.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Atossa Therapeutics in a report on Monday, August 12th. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Ascendiant Capital Markets boosted their price objective on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Atossa Therapeutics in a report on Thursday, June 20th.

Atossa Therapeutics Price Performance

The company’s fifty day moving average price is $1.36 and its 200-day moving average price is $1.41. The stock has a market cap of $178.57 million, a price-to-earnings ratio of -5.92 and a beta of 1.19.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, sell-side analysts forecast that Atossa Therapeutics, Inc. will post -0.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atossa Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Atossa Therapeutics by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after acquiring an additional 78,269 shares during the period. Renaissance Technologies LLC increased its position in shares of Atossa Therapeutics by 11.9% in the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after buying an additional 164,540 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after buying an additional 399,041 shares during the period. Rhumbline Advisers purchased a new stake in Atossa Therapeutics in the 2nd quarter worth $161,000. Finally, Virtu Financial LLC acquired a new stake in shares of Atossa Therapeutics in the first quarter valued at about $151,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.